EMA Authorised: Tivicay (dolutegravir) — ViiV Healthcare BV

View source ↗

Summary

EMA has authorised Tivicay (dolutegravir) for HIV infections, confirming regulatory approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare BV. Decision date: 16/10/2025